WW International (Nasdaq: WW) grows clinical arm as Q2 revenue falls

Rhea-AI Filing Summary

WW International reported Q2 2026 revenue of $162.3 million, compared with $189 million in combined Q2 2025, as Behavioral subscription revenue declined while the higher-priced Clinical offering expanded. Gross margin was 70.3%, Adjusted gross margin 73.6%, and net income was $14.1 million, with Adjusted EBITDA of $39.8 million (24.5% margin).

Total End of Period subscribers were 2.489 million, down 21.4% year-over-year, driven by a 24.6% decline in Behavioral subscribers, while End of Period Clinical subscribers grew 55.7% to 197 thousand. Core+, the higher-value Behavioral tier, reached 541 thousand subscribers and delivered a third consecutive quarter of sequential growth. Q2 marketing expense was $47.9 million, or 29.5% of revenue, after elevated peak-season spending in Q1. The company used $36.8 million of cash to reduce term-loan principal by $41.4 million, cutting annualized interest expense by about $4 million and ending the quarter with $101.5 million in cash. WW reaffirmed full-year 2026 guidance for $620–$635 million of revenue and $105–$115 million of Adjusted EBITDA.

Positive

• Clinical Subscription Revenue $39.9M grew 30.4% year-over-year, with End of Period Clinical Subscribers up 55.7% to 197 thousand, expanding the company’s higher-priced medical offering.
• Term loan principal cut by $41.4M in Q2 using $36.8M of cash, reducing annualized interest expense by approximately $4M and supporting liquidity alongside a $101.5M quarter-end cash balance.

Negative

• Q2 2026 revenue $162.3M declined about 14% from $189M in combined Q2 2025, reflecting a 22.7% drop in Behavioral Subscription Revenue.
• Total End of Period Subscribers 2.489M fell 21.4% year-over-year, with Behavioral subscribers down 24.6%, indicating ongoing contraction in the legacy digital and workshop base.

Filing Explained

Fresh-start accounting means WW’s post-June 24, 2025 financial statements cannot be directly compared with earlier periods.

This Form 8-K furnishes WW International’s completed second-quarter results and shareholder letter; because Q2 2026 is a Successor period, the filing says comparisons with periods before June 24, 2025 are not directly comparable.

WW attributes the split presentation to fresh-start accounting applied when it emerged from its financial reorganization, which means the Successor and Predecessor statements use different accounting bases.

The company combines selected revenue and operating metrics for trend analysis, but says those combined results do not represent the actual results it would have achieved without the accounting transition and may not indicate future results.

The filing also says it cannot reconcile the forward-looking Adjusted EBITDA outlook to net income without unreasonable effort because the required adjustments have not occurred, are outside the company’s control, or cannot be reasonably predicted; the corresponding GAAP effect therefore remains unavailable.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 Revenue: $162.3 million Q2 2026 Clinical Subscription Revenue: $39.9 million Q2 2026 Net Income: $14.1 million +5 more

8 metrics

Q2 2026 Revenue $162.3 million Quarterly revenue, compared with $189 million in combined Q2 2025

Q2 2026 Clinical Subscription Revenue $39.9 million Up 30.4% year-over-year versus combined Q2 2025

Q2 2026 Net Income $14.1 million Successor three months ended June 30, 2026; net income margin 8.7%

Q2 2026 Adjusted EBITDA $39.8 million Adjusted EBITDA margin of 24.5% for the quarter

End of Period Clinical Subscribers 197 thousand End of Period Clinical Subscribers, up 55.7% year-over-year

Total End of Period Subscribers 2.489 million Total End of Period Subscribers, down 21.4% year-over-year

Term Loan Principal Reduction $41.4 million Q2 reduction in outstanding term-loan principal; interest rate 10.53%

Quarter-End Cash Balance $101.5 million Cash and cash equivalents as of June 30, 2026

Key Terms

fresh start accounting, Adjusted EBITDA, GLP-1 medications, constant currency, +1 more

5 terms

fresh start accounting financial

"applied fresh start accounting which resulted in Successor and Predecessor financial statements"

Fresh start accounting is an accounting reset that occurs after a company emerges from a major restructuring or bankruptcy, where assets and liabilities are revalued to current fair values and a new equity base is recorded. Like wiping a chalkboard and writing a new starting score, it gives investors a clearer baseline for future performance but can make past results hard to compare and often changes reported profits, asset values and shareholder stakes.

Adjusted EBITDA financial

"We are reaffirming our full-year 2026 Revenue and Adjusted EBITDA guidance"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

GLP-1 medications medical

"access to GLP-1 medications when clinically appropriate"

GLP-1 medications are drugs that copy a natural gut hormone to help the body release insulin, lower blood sugar and reduce appetite by slowing how quickly the stomach empties. For investors, they matter because their strong clinical benefits have driven rapid sales growth, reshaped demand for diabetes and weight-loss treatments, and created regulatory, patent and pricing dynamics that can significantly affect healthcare companies’ revenues and profitability.

constant currency financial

"presentation of results on a constant currency basis in addition to reported results"

Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.

Chapter 11 financial reorganization regulatory

"related to the Company’s emergence from its Chapter 11 financial reorganization"

Chapter 11 financial reorganization is a legal process that lets a struggling company pause creditor actions and restructure its debts and operations under court supervision, similar to reorganizing a household budget while protected from bill collectors. For investors, it matters because the company’s shares can be sharply devalued, replaced or canceled and creditors may recover more or less than they would in a sale, so outcomes and ownership stakes often change significantly.

Earnings Snapshot

Revenue: $162.3 million · Guidance included

three months ended June 30, 2026

Revenue $162.3 million down 14% from $189 million in combined Q2 2025

Clinical Subscription Revenue $39.9 million up 30.4% year-over-year

Behavioral Subscription Revenue $121.5 million down 23% year-over-year

Net income $14.1 million compared with $1.3 million in the June 25–30, 2025 Successor period

Adjusted EBITDA $39.8 million compared with $4.4 million in the June 25–30, 2025 Successor period

End of Period Clinical Subscribers 197 thousand up 55.7% from 127 thousand a year earlier

Monthly Subscription Revenue Per Average Subscriber (ARPU) $20.90 up 10.2% from $18.97 in combined Q2 2025

Guidance

The company reaffirmed 2026 guidance for revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/05/2026 - 04:07 PM Accepted by SEC EDGAR 08/05/2026 - 04:05 PM Learn about SEC filing dates

FAQ

How did WW International (WW) perform financially in Q2 2026?

WW International generated Q2 2026 revenue of $162.3 million and net income of $14.1 million. Gross margin was 70.3%, Adjusted gross margin 73.6%, and Adjusted EBITDA reached $39.8 million, representing a 24.5% Adjusted EBITDA margin for the quarter.

What happened to WW International (WW) subscriber counts in Q2 2026?

Total End of Period subscribers were 2.489 million, down 21.4% year-over-year. Behavioral subscribers declined 24.6% to 2.291 million, while Clinical subscribers rose 55.7% to 197 thousand, shifting the mix toward the Clinical offering.

How are WW International’s (WW) Clinical and Core+ businesses performing?

Clinical Subscription Revenue was $39.9 million, up 30.4% year-over-year, with Clinical subscribers at 197 thousand. Core+, the higher-value Behavioral tier, reached 541 thousand End of Period subscribers and delivered its third consecutive quarter of sequential subscriber growth.

What 2026 guidance did WW International (WW) reaffirm?

WW reaffirmed full-year 2026 guidance for revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million. The company also expects Clinical Subscription Revenue to represent roughly 25%–30% of 2026 revenue, up from 16% in 2025.

How did WW International (WW) strengthen its balance sheet and liquidity in Q2 2026?

The company used $36.8 million of cash to reduce term-loan principal by $41.4 million, lowering annualized interest expense by about $4 million. It ended Q2 with $101.5 million in cash, and operating activities generated $24.3 million of cash during the quarter.

What happened to WW International’s (WW) ARPU in Q2 2026?

Monthly Subscription Revenue Per Average Subscriber (ARPU) rose to $20.90 in Q2 2026. This represented a 10.2% increase from $18.97 in combined Q2 2025, reflecting a mix shift toward Clinical and the higher-value Core+ Behavioral tier.

false 0000105319 0000105319 2026-08-05 2026-08-05 0000105319 stpr:VA 2026-08-05 2026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 5, 2026

WW INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Virginia		001-16769		11-6040273
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

18 West 18th Street, 7th Floor, New York, New York		10011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 589-2700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		WW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2026, WW International, Inc. issued a press release and a Shareholder Letter announcing its financial results for its fiscal quarter ended June 30, 2026. Copies of the press release and the Shareholder Letter are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including the text of the press release attached as Exhibit 99.1 and the Shareholder Letter attached as Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained in Items 2.02 and 9.01 of this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document or filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit		Description
Exhibit 99.1		Press Release dated August 5, 2026.
Exhibit 99.2		Shareholder Letter dated August 5, 2026.
Exhibit 104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				WW INTERNATIONAL, INC.
DATED: August 5, 2026				By:		/s/ Felicia DellaFortuna
				Name:		Felicia DellaFortuna
				Title:		Chief Financial Officer

3

Exhibit 99.1

Weight Watchers Announces Second Quarter 2026 Results

Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year

Core+ End of Period Subscribers of 541 thousand, up 13.9% year-over-year, reflecting third consecutive quarter of sequential growth

Revenue of $162.3 million; Clinical Subscription Revenue of $39.9 million, up 30.4% year-over-year

Reaffirms Full Year 2026 Financial Guidance

NEW YORK (August 5, 2026) – WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the second quarter of 2026 ended June 30, 2026¹ in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company’s Corporate Website.

“We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “Core+, our high-value Behavioral tier delivering tailored expert coaching and integrated weight health support, posted sequential subscriber growth for the third consecutive quarter, underscoring that members continue to embrace our holistic approach.”

“We are pleased with the continued momentum in Core+, which saw subscriber count grow 13.9% year-over-year and represents a clear signal that interest in our Behavioral business is stabilizing while our Clinical business continues to grow,” said Felicia DellaFortuna, Chief Financial Officer and member of the Company’s Interim Office of the Chief Executive. “End of Period Clinical Subscribers grew 55.7% year-over-year, and the sequential stability we saw in subscribers from Q1 to Q2 2026 reflects a deliberate recalibration of marketing investment following elevated peak season spend. We are reaffirming our full-year 2026 Revenue and Adjusted EBITDA² guidance. With a business that remains cash accretive and generated positive operating cash flow in Q2, we have confidence in our ability to continue building momentum into 2027 and beyond.”

Q2 Business Updates

• Q2 2026 Clinical Subscription Revenue grew 30.4% year-over-year and End of Period Clinical Subscribers grew 55.7% year-over-year, despite lapping significant prior-year growth in Q2 2025 from the Company’s former compounded semaglutide offering. End of Period Clinical Subscribers were flat compared to Q1 2026, as the Company strategically recalibrated its Clinical marketing investment following elevated spend in Q1 2026.

• Core+ represented 541 thousand End of Period Subscribers at the end of Q2 2026, up 13.9% from Q2 2025, representing the third consecutive quarter of sequential growth in the Company’s higher-value Behavioral tier.

• Q2 Monthly Subscription Revenue Per Average Subscriber (ARPU) increased 10.2% year-over-year, driven by the continued mix shift towards Clinical.

• Q2 Gross Margin was 70.3%. Q2 Adjusted Gross Margin² was 73.6%, which remained near record highs, reflecting continued operational discipline across the Company’s portfolio.

• Marketing expense was $47.9 million or 29.5% of Revenue, declining from $92.9 million in Q1 2026 as the Company moved past peak season and rebalanced investment across its business lines.

• Q2 Net Income was $14.1 million, which reflects higher depreciation and amortization related to Fresh Start Accounting¹. Q2 Adjusted EBITDA² was $39.8 million.

Balance Sheet and Liquidity Updates

• Cash and Cash Equivalents balance as of June 30, 2026 was $101.5 million.

• Operating activities generated $24.3 million of cash in Q2 2026, reflecting the cash-generative nature of the Weight Watchers business and continued commitment to maintaining a strong liquidity position as the Company executes its strategic priorities.

• In Q2 2026, the Company prepaid $36.8 million in cash to reduce the principal amount of its outstanding term loan. The prepayment was comprised of the following two components:

• In June 2026, $26.8 million in aggregate principal amount of prepayment from the annual cash sweep; and

• In May 2026, $10.0 million as part of the voluntary solicitation, which was fully subscribed at 68.5% of par.

As a result of these actions, the Company reduced the aggregate principal amount of its outstanding term loan by $41.4 million and reduced its annualized interest expense by approximately $4 million³.

2026 Guidance

The Company reaffirms its previously provided guidance for the year ending December 31, 2026.

• Revenue guidance of $620 million to $635 million.

• Adjusted EBITDA² guidance of $105 million to $115 million.

Second Quarter 2026 Conference Call and Webcast

The Company has scheduled a conference call today at 5:00 p.m. ET to discuss results. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

¹Fresh Start Accounting and Predecessor and Successor Periods

In connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the Company applied fresh start accounting which resulted in Successor and Predecessor financial statement presentation. References to “Successor” relate to the Company’s operations for the three and six months ended June 30, 2026 and the period from June 25, 2025 through December 31, 2025. References to “Predecessor” relate to the Company’s operations for the periods from March 30, 2025 through June 24, 2025 and December 29, 2024 through June 24, 2025. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or prior to that date.

²Statement regarding Non-GAAP Financial Measures

To supplement the Company’s consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. The Company presents in this release non-GAAP financial measures, including earnings before interest, taxes, depreciation and amortization expenses and share-based compensation expense (“EBITDA”); and for each period presented, EBITDA adjusted, as applicable, for (a) goodwill and other indefinite-lived intangible asset impairments, (b) reorganization items, net related to the Company’s emergence from its Chapter 11 financial reorganization, (c) gain on extinguishment of debt, (d) transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization, (e) net restructuring charges associated with the previously disclosed 2025, 2024, and 2023 restructuring plans, (f) non-recurring expenses in connection with the management of certain executive matters, and (g) other items such as the impact of foreign exchange gains and losses as indicated in the reconciliations below that management believes are not indicative of ongoing operations (“Adjusted EBITDA”). The Company also presents gross profit, gross margin, marketing expenses, selling, general and administrative expenses, and product development expenses on a non-GAAP basis that adjusts for similar items, as further indicated in the reconciliations below.

As exchange rates are an important factor in understanding period-to-period comparisons, the Company believes in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand the Company’s operating results and evaluate the Company’s performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company uses results on a constant currency basis as one measure to evaluate the Company’s performance. In this press release, the Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. The Company generally refers to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP and are not meant to be considered in isolation. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Management believes these non-GAAP financial measures provide useful supplemental information to investors regarding the performance of the Company’s business and are useful for period-over-period comparisons of the performance of the Company’s business. While the Company believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See “Reconciliation of Non-GAAP Financial Measures” in this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.

A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

³The interest rate in effect for the term loan as of June 30, 2026 was 10.53%.

Definitions

“Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to add on unlimited access to the Company’s workshops.

“Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by Weight Watchers Clinic and third parties combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops.

“Revenue” - “Subscription Revenue” consists of the aggregate of: (a) “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. In addition, “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

“Incoming Subscribers” - “Subscribers” refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill programs in Company-owned operations. The “Incoming Subscribers” metric reports Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“End of Period Subscribers” - The “End of Period Subscribers” metric reports Subscribers in Company-owned operations at a given period end. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“Monthly Subscription Revenue Per Average Subscriber” (“ARPU”) - The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each respective business are calculated as Subscription Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis.

About Weight Watchers

Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiatives, and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this press release to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: the Company’s recent emergence from bankruptcy, which could adversely affect its business and relationships and subjects us to risks and uncertainties; competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company’s failure to continue to retain and grow its subscriber base; the Company’s ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company’s ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; the Company’s ability to successfully implement strategic initiatives; the effectiveness and efficiency of its advertising and marketing programs across multiple platforms, including digital marketing and social media platforms; the impact on the Company’s reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners; the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company’s workforce; the Company’s chief executive officer transition, and its ability to appoint a new chief executive officer with the required level of experience and expertise in a timely manner; the Company’s ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, changes in tariffs and escalating trade tensions, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company’s business; the Company’s failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by us of leases; the inability to renew certain of the Company’s licenses, or the inability to do so on terms that are favorable to us; the dependence of the Company’s payments system on third-party service providers; the impact of the Company’s exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company’s debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company’s technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company’s ability to successfully integrate and use artificial intelligence in its business; the Company’s ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; the impact of existing and future laws and regulations; risks related to the Company’s exposure to

extensive and complex healthcare laws and regulations; the outcomes of litigation or regulatory actions; risks and uncertainties associated with the Company’s international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the Company’s ability to engage in share repurchases and pay cash dividends in the foreseeable future; risks related to the actions of activist shareholders and anti-takeover provisions in the Company’s articles of incorporation and bylaws; risks related to the actions of the Company’s shareholders and the exclusive forum provisions in its articles of incorporation; the possibility that the Company could fail to maintain the listing of the Company’s common stock on Nasdaq; and other risks and uncertainties, including those included in this press release and those detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this press release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:

Anna Kate Heller

WeightWatchers@icrinc.com

For media inquiries, please contact:

Melissa Garbayo

melissa.garbayo@ww.com

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

UNAUDITED

		Successor
		June 30, 2026				December 31, 2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	101,497			$	160,279
Restricted cash			5,796				6,298
Receivables (net of allowances: June 30, 2026 - $1,985 and December 31, 2025 - $1,651)			15,923				16,378
Prepaid income taxes			6,573				8,097
Prepaid marketing and advertising			3,079				9,275
Prepaid expenses and other current assets			14,017				13,277
TOTAL CURRENT ASSETS			146,885				213,604
Property and equipment, net			6,886				8,115
Operating lease assets			2,148				2,933
Goodwill			199,910				200,135
Other intangible assets, net			453,289				490,664
Deferred income taxes			16,068				16,482
Other noncurrent assets			15,256				14,825
TOTAL ASSETS		$	840,442			$	946,758
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Portion of operating lease liabilities due within one year		$	991			$	1,260
Accounts payable			22,537				9,212
Salaries and wages payable			20,366				34,375
Accrued marketing and advertising			12,238				22,985
Accrued interest			867				1,084
Other accrued liabilities			21,527				23,049
Income taxes payable			2,333				6,006
Deferred revenue			25,215				28,565
TOTAL CURRENT LIABILITIES			106,074				126,536
Long-term debt, net			423,995				465,466
Long-term operating lease liabilities			1,325				1,893
Deferred income taxes			29,858				34,021
Other noncurrent liabilities			540				771
TOTAL LIABILITIES			561,792				628,687
EQUITY
Successor common stock, $0 par value; 1,000,000 shares authorized; 9.999 shares issued at June 30, 2026 and 9,992 shares issued at December 31, 2025			379,690				378,777
Accumulated deficit			(100,021	)			(62,095	)
Accumulated other comprehensive (loss) income			(1,019	)			1,389
TOTAL EQUITY			278,650				318,071
TOTAL LIABILITIES AND TOTAL EQUITY		$	840,442			$	946,758

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

UNAUDITED

		Successor																Predecessor
		Three Months Ended June 30, 2026				Period from June 25, 2025 through June 30, 2025												Period from March 30, 2025 through June 24, 2025
Subscription revenue, net (1)		$	161,392			$	12,078											$	175,773
Other revenue, net (2)			932				89												1,224
Revenue, net			162,324				12,167												176,997
Cost of subscription revenue (3)			48,015				3,258												46,439
Cost of other revenue			167				—												50
Cost of revenue			48,182				3,258												46,489
Gross profit			114,142				8,909												130,508
Marketing expenses			47,875				2,784												32,093
Product development expenses			6,441				686												14,160
Selling, general and administrative expenses			50,352				2,853												42,851
Operating income			9,474				2,586												41,404
Reorganization items, net			—				—												(1,143,918	)
Interest expense			11,588				923												11,061
Gain on extinguishment of debt			(4,612	)			—												—
Other (income) expense, net			(421	)			932												4,478
Income before income taxes			2,919				731												1,169,782
Benefit from income taxes			(11,155	)			(523	)											(20,906	)
Net income		$	14,074			$	1,254											$	1,190,688
Earnings per share
Basic		$	1.41			$	0.13											$	14.81
Diluted		$	1.41			$	0.13											$	14.67
Weighted average common shares outstanding
Basic			9,999				9,987												80,419
Diluted			10,001				9,987												81,165

Note: Totals may not sum due to rounding.

⁽¹⁾ “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.

⁽²⁾  “Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

⁽³⁾  “Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company’s Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

UNAUDITED

		Successor																Predecessor
		Six Months Ended June 30, 2026				Period from June 25, 2025 through June 30, 2025												Period from December 29, 2024 through June 24, 2025
Subscription revenue, net (1)		$	328,749			$	12,078											$	360,953
Other revenue, net (2)			1,836				89												2,615
Revenue, net			330,585				12,167												363,568
Cost of subscription revenue (3)			97,460				3,258												100,026
Cost of other revenue			310				—												158
Cost of revenue			97,770				3,258												100,184
Gross profit			232,815				8,909												263,384
Marketing expenses			140,809				2,784												110,871
Product development expenses			14,534				686												25,281
Selling, general and administrative expenses			98,436				2,853												78,480
Franchise rights acquired impairments			—				—												27,549
Operating (loss) income			(20,964	)			2,586												21,203
Reorganization items, net			—				—												(1,143,918	)
Interest expense			23,064				923												38,664
Gain on extinguishment of debt			(4,612	)			—												—
Other (income) expense, net			(1,158	)			932												6,685
(Loss) income before income taxes			(38,258	)			731												1,119,772
(Benefit from) provision for income taxes			(332	)			(523	)											1,669
Net (loss) income		$	(37,926	)		$	1,254											$	1,118,103
(Net loss) earnings per share
Basic		$	(3.79	)		$	0.13											$	13.93
Diluted		$	(3.79	)		$	0.13											$	13.80
Weighted average common shares outstanding
Basic			9,998				9,987												80,271
Diluted			9,998				9,987												80,998

Note: Totals may not sum due to rounding.

⁽¹⁾ “Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.

⁽²⁾  “Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

⁽³⁾  “Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company’s Behavioral and Clinical services.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

UNAUDITED

		Successor																Predecessor
		Six Months Ended June 30, 2026				Period from June 25, 2025 through June 30, 2025												Period from December 29, 2024 through June 24, 2025
Operating activities:
Net (loss) income		$	(37,926	)		$	1,254											$	1,118,103
Adjustments to reconcile net (loss) income to cash (used for) provided by operating activities:
Depreciation and amortization			51,802				1,681												14,201
Amortization of deferred financing costs and debt (premium) discount, net			(51	)			—												1,766
Impairment of franchise rights acquired			—				—												27,549
Impairment of intangible and long-lived assets			3				—												97
Share-based compensation expense			840				—												4,032
Deferred tax (benefit) provision			(4,259	)			—												26,232
Allowance for doubtful accounts			27				—												(1,131	)
Foreign currency exchange rate (gain) loss			(1,059	)			933												6,717
Non-cash reorganization items, net			—				—												(1,176,532	)
Gain on extinguishment of debt			(4,612	)			—												—
Changes in cash due to:
Receivables			227				466												4,280
Prepaid expenses			6,978				586												(31,281	)
Accounts payable			12,357				406												(8,237	)
Accrued liabilities			(26,171	)			6,178												15,084
Deferred revenue			(3,178	)			47												(2,914	)
Other long term assets and liabilities, net			(599	)			—												(2,234	)
Income taxes			(3,654	)			(43	)											(30,155	)
Cash (used for) provided by operating activities			(9,275	)			11,508												(34,423	)
Investing activities:
Capital expenditures			—				—												(87	)
Capitalized software and website development expenditures			(11,935	)			(188	)											(6,253	)
Other items, net			—				—												(1	)
Cash used for investing activities			(11,935	)			(188	)											(6,341	)
Financing activities:
Borrowings on revolving credit facility			—				—												171,341
Financing costs			—				—												(1,298	)
Payments on long-term debt			(36,808	)			—												—
Taxes paid related to net share settlement of equity awards			—				—												(145	)
Cash paid for acquisitions			—				—												(16,000	)
Cash (used for) provided by financing activities			(36,808	)			—												153,898
Effect of exchange rate changes on cash and cash equivalents and restricted cash			(1,266	)			544												3,966
Net (decrease) increase in cash and cash equivalents and restricted cash			(59,284	)			11,864												117,100
Cash and cash equivalents and restricted cash, beginning of period			166,577				173,620												56,520
Cash and cash equivalents and restricted cash, end of period		$	107,293			$	185,484											$	173,620

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

														Variance
																		2026
		Successor												2026				Constant Currency
		Three Months Ended								Three Months Ended				vs				vs
		June 30, 2026								June 30, 2025				2025				2025
		GAAP				Constant Currency				Combined (1)				Combined				Combined
Selected Financial Data
Revenue (2)		$	162,324			$	161,523			$	189,163				(14.2%	)			(14.6%	)
Behavioral Subscription Revenue (3)		$	121,486			$	120,689			$	157,258				(22.7%	)			(23.3%	)
Clinical Subscription Revenue (4)		$	39,906			$	39,908			$	30,593				30.4%				30.4%
Subscription Revenue (5)		$	161,392			$	160,597			$	187,851				(14.1%	)			(14.5%	)
Other Revenue (6)		$	932			$	926			$	1,312				(29.0%	)			(29.4%	)

Note: Totals may not sum due to rounding.

⁽¹⁾  These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented.

⁽²⁾  “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

⁽³⁾  “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.

⁽⁴⁾  “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.

⁽⁵⁾  “Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.

⁽⁶⁾  “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

														Variance
																		2026
		Successor												2026				Constant Currency
		Six Months Ended								Six Months Ended				vs				vs
		June 30, 2026								June 30, 2025				2025				2025
		GAAP				Constant Currency				Combined (1)				Combined				Combined
Selected Financial Data
Revenue (2)		$	330,585			$	325,531			$	375,735				(12.0%	)			(13.4%	)
Behavioral Subscription Revenue (3)		$	250,010			$	245,006			$	312,981				(20.1%	)			(21.7%	)
Clinical Subscription Revenue (4)		$	78,739			$	78,741			$	60,051				31.1%				31.1%
Subscription Revenue (5)		$	328,749			$	323,746			$	373,032				(11.9%	)			(13.2%	)
Other Revenue (6)		$	1,836			$	1,784			$	2,703				(32.1%	)			(34.0%	)

Note: Totals may not sum due to rounding.

⁽¹⁾  These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented.

⁽²⁾  “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

⁽³⁾  “Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.

⁽⁴⁾  “Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.

⁽⁵⁾  “Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.

⁽⁶⁾  “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

OPERATIONAL STATISTICS

(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)

UNAUDITED

		Successor								Combined
		Three Months Ended								Three Months Ended
		June 30, 2026								June 30, 2025				Variance				Variance
						(Constant Currency)												(Constant Currency)
Incoming Subscribers (1)
Incoming Behavioral Subscribers			2,463				N/A				3,299				(25.4%	)			N/A
Incoming Clinical Subscribers			197				N/A				135				45.9%				N/A
Incoming Subscribers			2,659				N/A				3,434				(22.6%	)			N/A
End of Period Subscribers (2)
End of Period Behavioral Subscribers			2,291				N/A				3,040				(24.6%	)			N/A
End of Period Clinical Subscribers			197				N/A				127				55.7%				N/A
End of Period Subscribers			2,489				N/A				3,167				(21.4%	)			N/A
Monthly Subscription Revenue Per Average Subscriber (3)
Monthly Behavioral Subscription Revenue Per Average Subscriber		$	17.04			$	16.92			$	16.54				3.0%				2.3%
Monthly Clinical Subscription Revenue Per Average Subscriber		$	67.55			$	67.55			$	78.00				(13.4%	)			(13.4%	)
Monthly Subscription Revenue Per Average Subscriber		$	20.90			$	20.80			$	18.97				10.2%				9.6%

Note: Totals may not sum due to rounding.

⁽¹⁾  The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.

⁽²⁾  The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.

⁽³⁾  The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

OPERATIONAL STATISTICS

(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)

UNAUDITED

		Successor								Combined
		Six Months Ended								Six Months Ended
		June 30, 2026								June 30, 2025				Variance				Variance
						(Constant Currency)												(Constant Currency)
Incoming Subscribers (1)
Incoming Behavioral Subscribers			2,631				N/A				3,244				(18.9%	)			N/A
Incoming Clinical Subscribers			130				N/A				92				41.9%				N/A
Incoming Subscribers			2,761				N/A				3,336				(17.2%	)			N/A
End of Period Subscribers (2)
End of Period Behavioral Subscribers			2,291				N/A				3,040				(24.6%	)			N/A
End of Period Clinical Subscribers			197				N/A				127				55.7%				N/A
End of Period Subscribers			2,489				N/A				3,167				(21.4%	)			N/A
Monthly Subscription Revenue Per Average Subscriber (3)
Monthly Behavioral Subscription Revenue Per Average Subscriber		$	16.91			$	16.57			$	16.33				3.6%				1.5%
Monthly Clinical Subscription Revenue Per Average Subscriber		$	75.13			$	75.13			$	85.01				(11.6%	)			(11.6%	)
Monthly Subscription Revenue Per Average Subscriber		$	20.76			$	20.45			$	18.77				10.6%				8.9%

Note: Totals may not sum due to rounding.

⁽¹⁾  The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.

⁽²⁾  The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.

⁽³⁾  The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective year-to-date period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

		Successor																																Predecessor
																		Period from																Period from
		Three Months Ended																June 25, 2025																March 30, 2025
		June 30, 2026																through June 30, 2025																through June 24, 2025
														Selling,																Selling,																Selling,
										Product				General, and												Product				General, and												Product				General, and
		Gross				Marketing				Development				Administrative				Gross				Marketing				Development				Administrative				Gross				Marketing				Development				Administrative
		Profit				Expenses				Expenses				Expenses				Profit				Expenses				Expenses				Expenses				Profit				Expenses				Expenses				Expenses
GAAP		$	114,142			$	47,875			$	6,441			$	50,352			$	8,909			$	2,784			$	686			$	2,853			$	130,508			$	32,093			$	14,160			$	42,851
% of Revenue			70.3	%			29.5	%			4.0	%			31.0	%			73.2	%			22.9	%			5.6	%			23.4	%			73.7	%			18.1	%			8.0	%			24.2	%
Adjustments:
Transaction Costs (1)		$	—			$	—			$	—			$	—			$	—			$	—			$	—			$	(182	)		$	—			$	—			$	—			$	(10,049	)
Depreciation and Amortization Expenses			5,331				—				—				(20,585	)			330				—				(4	)			(1,347	)			4,147				—				(54	)			(3,086	)
Restructuring Charges (2)			—				—				—				156				—				—				—				—				(2,071	)			—				—				(977	)
Share-based Compensation Expense			0				(160	)			(109	)			(463	)			—				—				—				—				—				—				—				(3,171	)
Executive Related One-Time Costs (3)			—				—				—				(3,798	)			—				—				—				—				—				—				—				—
Total Adjustments		$	5,332			$	(160	)		$	(109	)		$	(24,690	)		$	330			$	—			$	(4	)		$	(1,529	)		$	2,076			$	—			$	(54	)		$	(17,284	)
Adjusted		$	119,474			$	47,715			$	6,332			$	25,662			$	9,239			$	2,784			$	682			$	1,324			$	132,584			$	32,093			$	14,106			$	25,567
% of Revenue			73.6	%			29.4	%			3.9	%			15.8	%			75.9	%			22.9	%			5.6	%			10.9	%			74.9	%			18.1	%			8.0	%			14.4	%
Currency Adjustment			(698	)			(41	)			0				(51	)			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
Constant Currency		$	113,444			$	47,834			$	6,441			$	50,301				N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
% of Revenue			70.2	%			29.6	%			4.0	%			31.1	%			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
Adjusted Constant Currency		$	118,775			$	47,675			$	6,332			$	25,610				N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
% of Revenue			73.5	%			29.5	%			3.9	%			15.9	%			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A

Note: Totals may not sum due to rounding.

⁽¹⁾  Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

⁽²⁾  Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.

⁽³⁾  Non-recurring expenses in connection with the management of certain executive matters.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

		Successor																																Predecessor
																		Period from																Period from
		Six Months Ended																June 25, 2025																December 29, 2024
		June 30, 2026																through June 30, 2025																through June 24, 2025
														Selling,																Selling,																Selling,
										Product				General, and												Product				General, and												Product				General, and
		Gross				Marketing				Development				Administrative				Gross				Marketing				Development				Administrative				Gross				Marketing				Development				Administrative
		Profit				Expenses				Expenses				Expenses				Profit				Expenses				Expenses				Expenses				Profit				Expenses				Expenses				Expenses
GAAP		$	232,815			$	140,809			$	14,534			$	98,436			$	8,909			$	2,784			$	686			$	2,853			$	263,384			$	110,871			$	25,281			$	78,480
% of Revenue			70.4	%			42.6	%			4.4	%			29.8	%			73.2	%			22.9	%			5.6	%			23.4	%			72.4	%			30.5	%			7.0	%			21.6	%
Adjustments:
Transaction Costs (1)		$	—			$	—			$	—			$	—			$	—			$	—			$	—			$	(182	)		$	—			$	—			$	—			$	(20,873	)
Depreciation and Amortization Expenses			10,512				—				—				(41,290	)			330				—				(4	)			(1,347	)			8,650				—				(115	)			(5,440	)
Restructuring Charges (2)			(65	)			—				—				(377	)			—				—				—				—				(2,455	)			—				—				(2,333	)
Share-based Compensation Expense			0				(301	)			(218	)			(899	)			—				—				—				—				—				—				—				(4,032	)
Executive Related One-Time Costs (3)			—				—				—				(5,362	)			—				—				—				—				—				—				—				—
Total Adjustments		$	10,447			$	(301	)		$	(218	)		$	(47,928	)		$	330			$	—			$	(4	)		$	(1,529	)		$	6,195			$	—			$	(115	)		$	(32,677	)
Adjusted		$	243,262			$	140,508			$	14,316			$	50,508			$	9,239			$	2,784			$	682			$	1,324			$	269,579			$	110,871			$	25,166			$	45,803
% of Revenue			73.6	%			42.5	%			4.3	%			15.3	%			75.9	%			22.9	%			5.6	%			10.9	%			74.1	%			30.5	%			6.9	%			12.6	%
Currency Adjustment			(4,389	)			(1,028	)			(10	)			(312	)			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
Constant Currency		$	228,426			$	139,781			$	14,524			$	98,124				N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
% of Revenue			70.2	%			42.9	%			4.5	%			30.1	%			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
Adjusted Constant Currency		$	238,874			$	139,480			$	14,305			$	50,196				N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A
% of Revenue			73.4	%			42.8	%			4.4	%			15.4	%			N/A				N/A				N/A				N/A				N/A				N/A				N/A				N/A

Note: Totals may not sum due to rounding.

⁽¹⁾  Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

⁽²⁾  Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.

⁽³⁾  Non-recurring expenses in connection with the management of certain executive matters.

WW INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(IN THOUSANDS, EXCEPT PERCENTAGES)

UNAUDITED

		Successor												Predecessor
										Period from				Period from				Period from
		Three Months Ended				Six Months Ended				June 25, 2025				March 30, 2025				December 29, 2024
		June 30, 2026				June 30, 2026				through June 30, 2025				through June 24, 2025				through June 24, 2025
Net Income (Loss)		$	14,074			$	(37,926	)		$	1,254			$	1,190,688			$	1,118,103
Net Income (Loss) Margin			8.7	%			(11.5	%)			10.3	%			672.7	%			307.5	%
Interest			11,588				23,064				923				11,061				38,664
Taxes			(11,155	)			(332	)			(523	)			(20,906	)			1,669
Depreciation and Amortization Expenses			25,916				51,802				1,681				7,287				14,201
Share-based Compensation Expense			732				1,418				—				3,173				4,032
EBITDA		$	41,155			$	38,026			$	3,335			$	1,191,303			$	1,176,669
EBITDA Margin			25.4	%			11.5	%			27.4	%			673.1	%			323.6	%
Franchise Rights Acquired Impairments (1)			—				—				—				—				27,549
Reorganization Items, net (2)			—				—				—				(1,143,918	)			(1,143,918	)
Gain on Extinguishment of Debt (3)			(4,612	)			(4,612	)			—				—				—
Transaction Costs (4)			—				—				182				10,049				20,873
Restructuring Charges (5)			(156	)			313				—				(1,094	)			(122	)
Executive Related One-Time Costs (6)			3,798				5,362				—				—				—
Other (7)			(421	)			(1,158	)			932				4,478				6,685
Adjusted EBITDA		$	39,764			$	37,931			$	4,449			$	60,818			$	87,736
Adjusted EBITDA Margin			24.5	%			11.5	%			36.6	%			34.4	%			24.1	%

Note: Totals may not sum due to rounding.

⁽¹⁾  The Company’s franchise rights acquired impairment charge related to its United States unit of account.

⁽²⁾  The net reorganization gain related to the Company’s emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject to compromise and the impacts of fresh start valuation adjustments.

⁽³⁾  Gain on extinguishment of debt consists of the Company’s voluntary prepayment in May 2026 of a portion of its New Term Loan Facility at 68.5% of par.

⁽⁴⁾  Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization.

⁽⁵⁾  Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.

⁽⁶⁾  Non-recurring expenses in connection with the management of certain executive matters.

⁽⁷⁾  Primarily consists of the impact of foreign exchange gains and losses.

Exhibit 99.2

WATCH IT WORK Q2 2026 Shareholder Letter August 5 2026 Weight watch

The global leader in science-backed weight management, combining science and community, helping our millions of members live their healthiest lives.

Business Update • Revenue: Q2 Revenue was $162.3 million, as we remain focused on driving subscriber mix toward our higher-value tiers. • Clinical Perfonnance: Clinical End of Period Subscribers grew 55.7% year-over-vear to 197 thousand at the end of 02 2026, despite 02 2025 including significant contributions from our former compounded semaglutide offering. Our clinical subscriber base held steady from Q1 2026 even as we reduced marketing spend following elevated peakseason spend and diversified our marketing Investments across our broader portfolio. • Core+ Growth: Core+ End of Period Subscribers reached 541 thousand at the end of Q2 2026, up 128% year-aver-,year, marking the third .consecutive quarter .of sequential growth, reflecting .sustained member demand .for tailored expert support and our Integrated support approach to weight health. • Markatlng Calibration: 02 marketing expense was $47.9 million, or 29.5% of Revenue, reflecting a reduction from our 01 2026 peak season spend of $929 million. • Gross Margin: Q2 Gross Margin was 70.3%. Q2 Adjusted Gross Margin1 was 73.6%, flat with Q1 and near record highs. • Profitability: 02 Net Income was $14.1 million, and Adjusted EBITDN was $39.8 million. • Debt Reduction and Liquidity: Q2 operations generated $24.3 million of cash. $36.8 million In cash was utilized in Q2 to reduce the aggregate principal amount of our term loan by $41A million. • Reaffirming .FY 2026 Guidance: We are reaffirming our previously provided .full year .Revenue guidance .of $620 million to $635 million and Adjusted EBJTDA1 guidance of $105 million to $115 million. Performance Indicators .Revenue rounded to the neare.st whole million Q22026 Q22025 %CHANGE Revenue $162M $189M (14%) Behavioral Clinical $l2lM $40M $l57M $31M (23%) 30% End of Period Subscribers 2.5M 3.2M (21%} Behavioral Clinical 2.3M 197K 3.0M 127K (25%) Monthly Subscription Revenue Per $20 90 $18 97 10% Average Subscriber (ARPU) 0 Successor Successor Predecessor .F 1 nanc1 al .M e t nc sI ll 022026 JunP .2er5io-d3 f0ro, .m20 25 Mar .3P0e-ri.Joudn fr 2o4m,. 2025 Gross Margin 70.3% 73.2% 73.7% Adjusted Gross Margin1 73.6% 75.9% 74.9% Net Income $14.tM $l.3M $l,t90.7M Net Income Margin 8.7% 10.3% ff72.7% Adjusted EBITDAi $39.SM $4.4M $60.SM Adjusted EBITDA Margin1 24.5% 36.6% 34.4% ~~~:!.~”:1”~.::.~:.a:~:-==:i~ci,:=~-=~~~=.:..=~~~ -I I 1L A racordllallon of tha l’Dlward-lDoklng .lull-AIIJuatad EBJTDA outlook Ill .nat Jru:ama cannot be pmvtdad w!lhout unraasanabla affort bacausa of .Iha lnhannt dlfflcully of accuratalv .faracastlng .Iha OCCJ1t111\C8 and flnanclal lmpBCt of .tha ,nu!ous adjusting JIB ma nllCOSlllllY far such niconcllJatfon .that haw .not “91 oa:urrad,””’ out of .Iha .Cmnpany’s cantml, or cmw,t be “””””1.llb p,:adk:md .For Iha sama “”””””””’” Campany Is unabla ,., ....., r,;_l,’,’”~~~~=:~=:’:,.ma=.s~U:~.1 =~bo==-hmrtaacounting.wllicll.....-mSuccaa8arandPrad8CIIIIOClr.financial.-mant 2 p,...n!atl0n.R.,._coo 111·-- IO<Wl’opom[ona ra, thlhJNmarrlha ondad Jw,e 30, 2026 and thapallod l’l’.l>m Juno 26, 2026111 Juno 30, 2026. Rolarancu,,, ._,. - 111 our -rallona lorlha JIOIIOd .ll’l>m March 30, 2025 lhrougll .lune 24, 2025. Accorttlng.ly, .the .conaolldated .llnanclal .iatementa an..r .Juno 24, 2025 are not “””’Pllral>Je .with .the “”’1B.O.lldot .nr.nclal atatement8 aa of .or prtor ID .thal .date.

To Our Valued Shareholders Weight Watchers was built on a conviction that has grown more relevant with every passing year: people are far more likely to achieve lasting weight health when they have the right support. For more than six decades, Weight Watchers has turned the lonely Journey of weight loss into a shared experience. Our members don’t come to us for a one-size-fits-all plan; they value access to real-life experts who see them, hear them, and can guide them through the uncertain and deeply personal Journey ahead. That is what Weight Watchers delivers: a holistic experience enabled by our tech platform and guided by experts. Our nearly 700 clinicians trained to support people with obesity are actively helping members understand and navigate the benefits and challenges of GLP-1 therapy. Members can meet one-on-one with a Registered Dietitian to craft a personalized nutrition plan that balances calorie targets with key macronutrients Uke protein and fiber to maintain healthy muscle mass. And when the road gets tough, they can connect with their fellow members to seek advice, swap tips, or simply vent during virtual experiences led by our expert coaches. One thing ls certain, wherever your path leads: with Weight Watchers to support you, you never have to walk it alone. Jn a market crowded with options that offer prescriptions without people, our human-centric approach - powered by technology that seamlessly connects members with expert coaches and clinicians - ls more differentiated and more valuable than ever before. Our opportunity continues to take shape Even as GLP-ls continue to redefine our sector, recent developments demonstrate the enduring power of the Weight Watchers model. Weight Watchers has always led with science, and we continue to do so in the GLP-1 era Today, with more than 1 in 10 Americans using GLP-1s for weight loss - a number that has Quadrupled since 20241 - we are expanding medication access for our Qualified members. Starting in Q2, patients can access the Weight Watchers Med+ program from LillyDlrect, creating another meaningful channel for members to discover our Med+ program. We also recently announced that Weight Watchers will support members seeking access to GLP-1 medications under the Medicare GLP””.1 Bridge Program. These new pathways build on our ongoing efforts to expand accessibility and help our members secure the lowest possible price for their medication, whether they are leveraging insurance or paying out of pocket. As GLP””.1 adoption grows, the need for comprehensive weight health programs grows with it. Medication Js a powerful too~ but for many it Isn’t the whole answer. GLP-ls were approved as an adjunct to a reduced-calorie diet and increased physical activity - and global health guidance points the same way2• Furthermore, clinical research underscores two critical realities: that most people don’t stay on these medications long-term3; and that those who stop often regain the weight’. .Sae .”S.ourC811” within .~Sources, .O.aflnltlons, and Flnanclal .O&talla” .aactlon .for .f.urthar detail .on .footnotes. -I I 3

That is why we believe Weight Watchers’ offerings are more relevant than ever as people navigate their journey with medication. Med+ Members who regularly engage with our GLP-1 Success Program lose 29% More body weight at 12 months, on average, than those who use medication without this structured behavioral support5 Weight Watchers Med+ members prescribed GLP-1 medications reported over 30% More body weight lost on average, at 12 months, than select competitors6. Weight Watchers members reduced their calories from ultra-processed foods by 29% More a tangible marker of the real behavioral shifts from our approach7. We are leveraging our decades of data, experience, and consumer insights to build a tech-enabled, integrated portfolio of offerings that meets our members at every stage of their weight loss journey. This holistic ecosystem includes: Core, our Base behavioral offering anchored by Weight Watchers’ signature Points Program. Core+, our higher-value Behavioral offering that adds unlimited workshops, coaching, and our GLP-1 Success Program — which is available to members prescribed GLP-1s through an outside provider. Med+, our Clinical offering that combines the above tools, including our GLP-1 Success Program, with access to clinicians and GLP-1 prescriptions for qualified members. With a range of options available, members can choose the level of support that fits their needs over time. As the conversation around weight health shifts and the limitations of medication-only approaches become clearer, we believe that Weight Watchers’ unique combination of clinical care, behavioral depth, and technology-enabled human support is an enduring competitive advantage that positions the Company for long-term success in this rapidly growing market. Encouraging momentum behind our business Core+ Growth: Core+ subscriber growth continued its sequential trend in Q2, with Core+ End of Period Subscribers of 541K, up from Q1 2026, an increase of 13.9% from Q2 2025. This growth demonstrates a meaningful and sustained demand for our higher-value Behavioral tier, which includes tailored expert support, virtual workshop experiences, and community programming. Clinical Performance: Q2 End of Period Clinical Subscribers held steady from Q1 at 197K as of June 30. Following elevated Clinical marketing investment in Q1, we strategically recalibrated our spend in Q2. New Strategic Collaborations: We recently launched several new strategic collaborations, including partnering with Sam’s Club to bring Weight Watchers’ programs to their members, connecting the support of our platform with Sam’s Club’s focus on healthy eating and everyday value. The partnership also advances our mission to make weight health more accessible by giving Sam’s Club members a path to prescription support through their trusted pharmacy service.

Maintaining a strong financial foundation Our continued focus on operational and marketing discipline contributed to an improved financial profile in Q2. Last quarter, we told you what to expect: ongoing discipline, durable cash generation, and a meaningful reduction in our debt. We delivered on those commitments and continue to make progress on our multi-year transformation. As we execute on our long-term strategy, we remain committed to durable cash generation while preserving financial flexibility to invest in our most critical strategic priorities. Revenue: Q2 Revenue was $162.3 million, including Clinical Subscription Revenue which grew 30.4% year over-year to $39.9 million despite significant contributions in Q2 2025 from our former compounded semaglutide offering. Gross Margin: Q2 Gross Margin was 70.3%. Q2 Adjusted Gross Margini was 73.6%, remaining near record highs. Reaffirming FY 2026 Guidance: We are reaffirming our previously provided full year 2026 Revenue and Adjusted EBITDA guidanceii of $620 million to $635 million and $105 million to $115 million, respectively. Strengthened Cash Position and Debt Reduction: In Q2, we delivered on our previously stated commitment to meaningfully reduce our debt, utilizing $36.8 million in cash to reduce the aggregate principal of our term loan by $41.4 million. We ended the quarter with $101.5 million in cash and operating activities generated $24.3 million of cash in the quarter, reflecting the cash-generative nature of our business and our continued commitment to maintaining a strong liquidity position as we execute our transformation. Looking forward: Leaning on our differentiator Losing weight remains one of the most personal journeys a person can take, and one that rarely follows a straight line. As the limits of medication-only care become increasingly clear, Weight Watchers’ unique combination of experience, empathy, and data will continue to set us apart and keep members engaged with our supportive, compassionate community. As we enter the second half of 2026 and look toward 2027, we remain confident in our ability to both deliver superior health outcomes for our members and create long-term value for shareholders. We will continue to pursue targeted investments, partnerships, and improvements that lay the foundation for durable growth, and we are committed to executing with discipline and conviction to support every Weight Watchers member with the human-centric, expert-led guidance that they need to achieve lasting weight health outcomes. Felicia DellaFortuna, Chief Financial Officer Jon Volkmann, Chief Operations Officer Members of the Interim Office of the Chief Executive 15116-004 04Aug26 15:15 Page 3 See “Reconciliation to GAAP Measures of Non-GAAP Financial Measures” for further detail on adjustments to the most comparable GAAP financial measures. A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Integrated Care Model Our weight health offerings range from digital behavioral tools to personalized coaching and medical solutions, allowing us to meet members where they are on their weight health journey, while providing ++opportunities $&(( ( for ARPU expansion. )&’ $ Behavioral Tools Science-backed behavioral tools including Points® Program and tailored nutrition guidance enables members to adopt liveable, lasting habits Community & Connection Experts, coaches, peers that provide support, accountability, and fun Tailored Programs Programming & content tailored for specific life stages and clinical areas such as GLP-1 Success and Menopause to meet members where they are

-I I Superior Health Outcomes Weight loss at 6 months• Weight loss at 12 months• mm mmm0 1-1 .Calibrate Hlms.&Hers Ro .Calibrate Form .Hulth .Hims• Hens 7 .See .”Saurcelt’ within .”.So.ur.ces. D.elinitions. and .Financial .D.atails” section for .further .detail on .footnotes.

Q2 Financial Pelformance and 2026 Outlook

.Subscribers and ARPU Continued growth within Core+, our higher-value Behavioral offering Monthly Subscription Revenue Per Behavioral and Clinical ARPU! Average Subscriber (ARPU}1 $20.59 $20.90 -+-Clinical -+-Behavioral $78.00 $79.23 $68.52 $70.82 $18.97 $18.52 .+10j{,Y/Y $16.54 $16.39 $16.32 $16.82 Combined Q3 2025 Q4 2025 Ql 2026 Q2 2026 Combined Q3 2025 Q4 2025 Ql 2026 Q2 2025 Q2 2025 ARPU Increased 10.2% year-over-year, reflecting a shift ln mix of our subscriber base to Clinical and Core+ membership tier. End of Period Subscribers’ (k) End of Period Clinical Subscribers grew 55.7% year-over-year to 197 thousand at the end of Q2 2026 compared to 127 thousand at the end of Q2 2025. This reflects an acceleration from 45.9% year-over-year growth at the end of Q1 following marketing investment in peak season. Within Behaviora~ Q2 Core+ End of Period Subscribers Increased 12.8% year-over-year. We are seeing members shift from Core to our Gore+ and Med+ tiers, a trend that we expect to continue. End of Period Behavioral Subscribersi (k) End of Period Clinical Subscribersi (k) $17.04 Q2 2026 +56%Y/Y -25”YIY 3,040 2,862 2,631 2,463 2,291 197 197 127 124 130 Combined Q3 2025 Q2 2025 Q4 2025 Ql 2026 Q22026 Combined Q3 2025 Q2 2025 Q4 2025 Ql 2026 Q2 2026 L Management .bllUIIVU that .the key Pll[1’omianllll metnc,s .such as Subs.c!Jptlon Reveruie. Jnc:omlng and End .or .Pertod .Subscribers .and Monll!ty S\lb,Gllptlon Rwem1e .Par /wer,4IJi -I I Subscdbllr .for .the .Succmiaor Ptlltad .whan camblruld with .the .Pred8CllBSlll’ Pa1od pmvfdas mora meaningful comparisons lD other periods and an, usaful In ldantlfylng CWJ1111t b.ualnass 9 .trenda. Acco~ the charta and .table8 In .thla ahan!:holder letter present .the .combined results .fDr the .three montha ended .June 30, 2025 aa .Combined Q2 2025.

Revenue and Gross Margin Near-record Adjusted Gross Marginsi reflect operational efficiency across the portfolio Q2 Revenue was $162.3 million. Clinical Subscription Revenue grew 30.4% year over year to $39.9 million and represented 24.6% of total Revenue, compared with 15.9% of full year 2025 Revenue. Behavioral Subscription Revenue decline continues to be concentrated in our Core tier, with subscriber growth in our Core+ offering helping to offset Core tier declines. 189 Combined Q2 2025 172 Q3 2025 ¦ Clinical Revenue11 ($m) 163 168 162 ◄Hit& Q4 2025 Ql 2026 Q2 2026 ¦ Behavioral ¦ Other Gross Margin in Q2 2026 was 70.3% and Adjusted Gross Margin• was 73.6%, with Adjusted Gross Margin’ near record highs. Even as our revenue mix has continued to shift, our Q2 Adjusted Gross Margin’ was flat compared to Qt, reflecting the structural gains achieved through workflow automation and operational efficiency. 75.9% Gross Margin %of Revenue 74.9% 75.1% 74.4% •====+====:~=========:==-----~.._ __ _:._73~.~6~%~---...:7~3.6% 73.7% Predecessor 3/30/25- 6/24/25 73.2% Successor 6/25/25- 6/30/25 72.1% Successor Q3 2025 -+-GAAP Gross Margin 70.1% Successor Q4 2025 70.5% Successor Ql 2026 70.3% Successor Q2 2026 -+-Adjusted Gross Margin; L See .”.Reoonciliation .to .GAAP .Measures af Non-.GAAP .Financial .Measwe.s” .for .further detail on Jldjulrunents .to the mo.st oomparable GAAP .financial .measures. -I I IL Theae amounts .ccmbll\9 .the revenue 0.f .the .Succesecr and Predecessor partoda .for comparablUty purposes. Altl\ough .the .Successor and .Predl1C81180r haw a dlfl’erent accounting .basis due to the application Qf flesh start accounting, none Qf the flesh start accounting adjustments imp;,ct revenue. Therelo<e, the combined revenue amounts presented are cc”5istent with a .pro .forma prasantatkln .under Article .t1 or .Regulatton .S-X as If .traah start accounting was appllad at .the baglnnlng at .Iha .flrat period presented. 10

Operating Expenses Marketing investment rebalanced following peak season Predecessor 3/30/25- 6/24/25 Operating Expenses1 %of Revenue Successor 6/25/25- 6/30/25 Successor 03 2025 Successor 04 2025 Successor 01 2026 Successor 02 2026 ¦Marketing ¦Selling, General & Ad min Product Development Adjusted Operating Expenses1•11 %of Revenue Predecessor Successor 3/30/25- 6/25/25- 6/24/25 6/30/25 Successor 03 2025 Successor 04 2025 ¦Marketing ¦Selling, General & Ad min Successor 012026 Successor 02 2026 Product Development • Marketing expense In Q2 2026 was $47.9 million, or 29.5% of Revenue, reflecting a deliberate reduction from peak-season Levels and a more balanced allocation of Investment across our portfolio. • Selling, General & Administrative expenses were 3t.0% of Revenue, primarily driven by higher depreciation and amortization related to Fresh Start Accounting. Adjusted SG&A11 was $25.7 million, or t5.8% of Revenue. • Product Development expense was $6.4 million. or 4.0% of Revenue, as we continued to execute against our multi-year technology roadmap. L ln connection with the Company’s emergence from Jts llnanclal reorganlzatlon precess on June 24, 2025, the Company applied !mah start accounting .which resulted In Successor and Prede088ll0r .nnanclal .statement prasentatlon. .Ra!e111ncea .to “.S.uCC88110r:” ralate .to .ow operations .for periods after .June 24, 2025. Re!erancee .to .·Pradecesaor” mlate .to .our operations .!or -I I the three months ended March 29, 2025 and the period trcm .Man::h 30, 2025 through June 24, 2025. Accordingly, the consolidated financial statements after June 2A, 2026 are not _1 _ comparable .with the consolidated .flnenclal statements as .o! .or prior .to .lhet date. 1 lL S.ae .”Raconclllatlon .to .GAAP Measwes .of .Non.-OAAP .Financial MeaaurBS” .!or lwther .detail .on adjustments .to .Iha most .comparable GAAP .llnanclal measwes.

Profitability .Q.2 Profitability .F.oUows Strategic .Q.1 .l.nvestme.nt I i .02 2026 .Net .Income was $14.1 mlWon .which Included .$25.9 mlWon .of depreclatton and amortization, .the malor.lty .of which related .to Frash .Start Accounting. AdJus:tad .EB£TDAI was .$39.B million (24.5% margin). reflecting str.ong operating per.fOn’nanc.e and diseiplined expense management. .N.et (Loss) J.ncome ($m} and .Ne.t (Loss) In.co.me MarglnD 1,191 Predecessor 3/30/25- 6/24/25 10% 1 Successor 6/25/25- 6/30/25 (33%) -(58) Successor Q3 2025 ¦ Net (Loss) Income (Sm) (4%) (6) Successor Q42025 (31%) -(52) Successor Ql 2026 ♦ Net (Loss) Income Margin 9% 14 Successor Q2 2026 Adiusted .EB.ITDA {$m) and Adiusted .EB.ITDA .Margi.nlJ1 37% 34% ♦ ♦ 25% 24% ♦ ♦ 11% ♦ 4 -- 1% ♦ -2 Predecessor Successor Successor Successor Successor Successor 3/30/25- 6/25/25- Q3 2025 Q42025 Ql 2026 Q22026 6/24/25 6/30/25 ¦ Adjusted EBITDA (Sm) ♦ Adjusted EBITDA Margin 1.8M.- l?llnn.11>GN,f>-afllo.rH:AAP.F!Jwml-fbr--a,~to!hommt~GN,f>llnlnollf.Llll---”’ 111.-~-llol’ll~.”-dll,l~-C111-””-~~.-~llllll,dhNl>fttt~~_-,lft4--,d P,t.P :.11001111&11CM!_ti, ___ !O~--Jo<U-,ti011tfer~-~Z4,Z0211.-.1D.’l’Jed_._!0””1--!0r.ttle 12 ----2fl,2ll21’,.wllll.t$llflad.flcm-Xl,2Dllll\lal.dlJ-.zc,202&.~.-------.-JM,:imtil1111nat .............. • lMl!l.b~JIJW.ftdlll-Mt/ll)Jo,icrto-date.

Cash Flow and .Balance .Sheet Debt reduced by $41.4 million while liquidity ls preserved Cash($m)1 Cash from Operations ($m)l 24 12 170 ¦ 160 - 152 - - 121 101 (3) (3) (34) (49) Successor Successor Successor Successor Successor Predecessor Successor Successor Successor Successor Successor 6/30/25 9/30/25 12/31/25 3/31/26 6/’30/26 3/30/ 25- 6/ 25/25- Q3 2025 Q4 2025 Q12026 Q2 2026 6/24/25 6/30/25 cash and Cash Equivalents were $101.5 million at the end of Q2 2026. Cash Flow from Operations generated approximately $24.3 milUon of cash In the quarter, which includes $12.3 million of quarterly interest to service our term loan. Furthermore, the cash balance at the end of Q2 reflects the $36.8 million cash payment made to reduce our term loan and capital expenditures of $6.1 million. We have fundamentally transformed our balance sheet following our Q2 2025 Financial Reorganization: Term Loan N$465 million outstanding, a reduction in total debt of over 70% from $1.6 bl.lllon as of Q2 2025 $.424 million outstanding as of Q2 2026 Maturity Interest Rate June 24, 2030 SOFA + 680 basis points, subject to certain conditions Cash Sweep Annual prepayments for excess cash above $100 million, .b.ased on the last .10 calendar days of .the first quarter -I I L In mnnac:t!an .with .Iha Cmnp,any’s snwgaru:a .fmm Its .financial raorgenlmtlon .pmcaas on June 24, 2025. .th& Company appllad .fnlsh start JICCllUfll!ng which 1BB.11ltad In s.uccas,,.,, end Predecaalor .nnanc:MI 1ltll!ell\ent prN81’1tatlon. .Rerenmoas .to ~s11cceaa.or.” relate .to our .aperallon8 ror per1Qd8 artar .June 2-4, 2025. Rar.erencea .to .”Pre.d.ea11801”’ re!llte .to 011r OjlllratlOns .ror .tile !hr&a months anded March 29, 202li end .Iha period .fmm .Mardi 30. 2026 through June 2A, 2026. Aaconl!ngty, .th& oonlilllldats.d financial -ants aftar June 24, 202li ara nat 00JT1pambls wlll1 tile consolldlll8cl ftnandal .statements• of or pr1o1 to that date. 13

2026 Outlook We are reaffirming our previously provided 2026 guidance for Revenue to be $620 million - $635 million and Adjusted EBITDA1 to be $105 million - $115 million. Revenue We continue to expect Clinical Subscription Revenue to be approximately 25% - 30% of 2026 Revenue, up from 16% of 2025 Revenue, which incorporates moderate declines in Clinical Subscribers in the remaining quarters of the year. This is driven by lower levels of marketing spend, more balanced allocation of that spend across our lines of business following Q1 which was more heavily focused on Clinical, and lapping the introduction of 12 month long term commitment plans. Within our Behavioral business, we are encouraged with the growth we are seeing within Core+ and we expect to grow Core+ subscribers in 2026. Gross Margin We continue to expect a modest Adjusted Gross Margin11 decline in 2026 versus 2025, and expect to remain above 72.0%. Operating Expense We expect 2026 Marketing Expense as a percentage of Revenue to increase modestly compared to 2025, with second half spend below first half levels. We expect Product Development to remain near the 02 2026 quarterly run-rate. We expect modest SG&A savings in 2026, primarily driven by the exit from our corporate headquarters lease and ongoing operational discipline. Cash Generation With peak marketing investment behind us, we expect to continue generating cash through the remainder of 2026. We expect approximately $45 million - $50 million of Interest costs for the full year 2026, reflecting lower quarterly interest following the 02 debt prepayment; quarterly capital expenditures In line with the Q2 run-rate; and cash taxes of between $5 million and $10 million. Looking Ahead Our second quarter results demonstrate the earnings power of a more disciplined operating model: a meaningfully smaller debt load, positive operating cash flow, and Core+ delivering its third consecutive quarter of sequential subscriber growth, all achieved while managing through a period of deliberate marketing recalibration. We remain confident in our financial footing and in the multi-year transformation ahead . .L A reconciliation .of .the forward•looktng .full year Adluated .EBITDA .outlook to net .Income .cannot .be .Provided without unr.88110nable effort bec.aues .of .the .Inherent .dlfflcult.v .of accurately -I I forecasting .the occurrence and .llnanclal Impact .of .the .llllllous adjusting Items neceassry .for such reconciliation that luM! not yet .occurred, are .out of .the Company’s centre~ .or cannot be .reasonably predicted .For .the same reasons, .the Company ls unable .to assess the prol>able stgnltlcance of .the .unavailable lntormstton, which .COLlld haw s .material Impact on Ila .future .GAAP .14 .financial results. IL .S.ae .”.Reconclllatlon .to .GMP .Measures .of Non-.GAAP flnanclal .Measures” .fer .further detail .on adjustmanta .to .the most .comparable .GAAi’ .flnanclal measures.

Second Quarter Conference Call and Webcast The “- Company has scheduled a conference # !-” “ call today at 5:00 p.m. ET to discuss results. The webcast of the ## # -# conference call will be available on the Company’s corporate - # website, corporate.ww.com, under Events # # and # # # Presentations. A replay of the webcast will be available on this site for at least 90 days. 4 About N4MNQHS>D>NHSPE@=EE;KD5>QD Weight QSR=MQ8;PN0M5MPS0 Watchers N@?SD5PM5D5 PKMNS;>633@KN>2>NS0=6DENGKNHS)1,R. Weight Watchers is the global SMNNQ@0=DS>>Q leader in science-backed N-QSO3KNS0SDMN@5Q6BD5PRS;PSNSQH5@EP2M5;weight management, offering an integrated support H60M5Q@5SQN@54DH0@KSNH5IC2SMK>@GSO3KDS5QS4SPHN4MNHSK>D>NHS0@>N>N system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, S;Q@00SKQDME and SDHN0M5MP0 human connection5N3K@PKM0D5NHSKE;;D . With more than 60 years of experience, K;NHK@6 HDN>L@ Weight Watchers *A;@QN@RK@0 is the most studied S;S;DPHRE> commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss 3K@PK0(>H@ED>DQ3> )1,R. program. 0SDQMD@>HS5QD5DQM2M33@3KDNSM5;MPE@=E5@K8@GQ@MQHS>M;Q@0065D2>633@ Its holistic, personalized M’S;M approach MHME>@D5Q6S>*AR=M> also includes U.S.-based ;QED5DMED5S clinical interventions S5ND5>M;MQQS>N@and access to AD5S. GLP-1 medications &I%NHSQ@03M52H>ES;DNH>DSQSN@;D when clinically appropriate, and a global KDN>0S0=SK>NHS3SK network of coaches and D’S;>63@KNNHS25S;N@community support. KSMQHM5;> Since 1963, the company 5NH KP@ has >9S led with = >Q5MQQ science to deliver >NS S>@6ND@>;DKQNE2@KNHK@6PH4DPHN4NQH its members the personalized support they need >G@Kto $ reach 6>D5S>>G6EER>3SNK603EMNG@0G@KS03E2 and sustain their goals. Members can access >HMEH3EM5>M;3M2K>(5MEM5;>M3SQK@;;DNHthese solutions directly, or through Weight Watchers for Q5NMDQ@K2MDQSD>@EMNDPM33>M;@5SR>‘SR-N>RME>@E6ND@>4N4MNQHSK>@?SK>M3@S53MNH Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path G@KM;NH NHSDK=@;2M5;EDSME@5PSKHSMENHDSKEDGSJ@K0@KSD5G@K0MND@5D>DNSDPHNMNQHSK>Q@0 forward that ND>K@@N;D5K>SMKQHPK@65; is rooted in research, grounded ;D5S3MNH2M5;;S>P5S;N@HSE3SSK20S in empathy and designed to help every member =SKGSSE=SBSKD5 feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com “Weight Watchers is the only reason “Weight Watchers I’m still on a GLP-1. isn’t one-size-fits-<7;(47&4. I got nutrition, -&!7 (×7%-×,67 all. It fits this stage \[ZK? ) 0 community, (7$$ #87 #&-4>!73&‘5 $(. and ,6 \[ZK? of life.” a^^]H^ so much more.” ]H%]H^ 449S0=SK z1S>E2~ -Lesley, EOLNOKJJ? Q z,M2E2~ 449S0=SK -Hayley, EOLNOKJJ? ççç WW Member UWVV[TR ECA@CBD? IHGF WW Member ECA@CBD? U”![TR äãâàßÞáÝã

Sources, Definitions and Financial Details

Sources tMed+ members given the .GLP-,1 Companion Program .lo.st Zl .lbs, on average, after .6 months. .Based on a .6-month .clinical trial Cn=180l of .individuals .who were .enrolled between February-April 2024, with overweight .or obesity taking semaglutide .or tirzepatide Jor weight .loss and .related outcomes through the Med+ Program and participating .in the GLP-1 Success nutrition program. Heinberg et al. Effectiveness of Telemedicine Prascribing .and a Long-Acting Obesity .Medication .Behavioral Program: A 24.~Week S.ingle-Arm Study. Obesity. 2025 .. Funded by WW International, Jnc.

Based on an internal .data analysis or .142 Weight .watchers Med+ Menopause program members .who requested a refill or .their .honnone therapy through Weight .watchers and self reported symptom .scores .before and after participation in the program. After an average .of .43.6 days, average composite menopause symptom scores decreased from 221 to 10.5, out of a possible 40 points. Not a randomized, controlled clinicaltlial. Selfreported outcomes .have not been independently verified. .Individual .results may vary. .1. 8 .Based on an internal data analysis of t7IVI .Core program .members .who didn’t refer someone compared to .82K.Core program members .who did, .conducted from April 2022-April 2023

Fresh Start Accounting and Predecessor and Successor Periods Jn connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the Company’s second quarter ended June 30, 2025 includes a “Predecessor” period from March 30, 2025 to June 24, 2025, and a IISuccessorn period from June 25, 2025 to June 30, 2025. Additionally, the Company qualified for and applied fresh start accounting. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or prior to that date. The Company’s third quarter ended September 30, 2025, fourth quarter ended December 31, 2025, first quarter ended March 31, 2026 and the second quarter ended June 30, 2026 all represent a Successor period. Although GAAP requires that we report our results for the period from March 30, 2025 through June 24, 2025 (Predecessor) and the period from June 25, 2025 through June 30, 2025 (Successor) separately, management views certain metric and revenue information for the three months ended June 30, 2025 by combining the results of the applicable Predecessor and Successor periods because management believes such presentation provides the most meaningful comparison of our results to prior periods. Although the Predecessor and Successor periods are generally not comparable as they are impacted by fresh start accounting, there are no fresh start adjustments affecting revenue and therefore revenue information has been combined in this letter to provide a meaningful understanding of operating trends, which would be consistent with a pro forma calculation under Article 11 of Regulation S-X. Nevertheless, the combined operating results do not reflect the actual results we would have achieved absent our emergence from its financial reorganization process and may not be indicative of future results. We cannot adequately benchmark the operating results of the period from June 25, 2025 through June 30, 2025 (Successor) against any of the previous periods reported In our consolidated financial statements without combining it with the period from March 30, 2025 through June 24, 2025 (Predecessor) and do not believe that reviewing the results of this period in isolation would be useful in identifying trends in or reaching conclusions regarding our overall operating performance. Management believes that the key performance metrics such as Subscription Revenue, Incoming and End of Period Subscribers and Monthly Subscription Revenue per Average Subscriber for the Successor period when combined with the Predecessor period provides more meaningful comparisons to other periods and are useful in identifying current business trends. Accordingly, this shareholder letter presents the combined results for these metrics for the three months ended June 30, 2025. -I I 19

Definitions and Performance Indicators .. Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to add on unlimited access to the Company’s workshops . .. Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by Weight Watchers Clinic and third parties combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops . .. Revenue!’ - “Subscription Revenue!’ consists of the aggregate of: (a) “Behavioral Subscription Revenue!’. the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) “Clinical Subscription Revenue”. the fees associated with subscriptions for the Company’s Clinical offerings. Jn addition, “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. “Revenuen consists of the aggregate of Subscription Revenue and Other Revenue. “Incoming Subscribers!’ - “Subscribersn refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill programs in Company-owned operations. The “Incoming Subscribers!’ metric reports Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends. “End of Period Subscribers!’ - The IIEnd of Period Subscribersl’ metric reports Subscribers Jn Companyowned operations at a given period end. Recruitment and retention are key drivers for this metric. Management utiUzes this metric to monitor changes Jn the subscriber base which directly impacts our revenue growth and trends . .. Monthly Subscrlption Revenue Per Average Subscriber” ( .. ARPU”) - The !’Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for our offerings divided by the Average Subscriber for our businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each respective business are calculated as Subscription Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each respective business Js the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis. -I I 20

Cautionary Note on Forward Looking Statements Thi.s .shareholder .le.tter .include.s “forward-looking .statements,” within .the meaning of .S.e.ction 27A of .the .S.e.curiti.e.s Act of 19.3.3, as amended, and .Section 21E of the .Securities Exchange Act of 19.34, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiative.s, .and prospects. The Company generally uses the word.s “may,’’ “wn~• “.could,” “expect,” “anticipate,” .”.believe,” •estimate; “plan,” “.i.ntend,” “aim” and similar expressions in this share.h.o.ld.er .Letter to identify forward-looking .statements. Th.e Company base.s .these forward-looking statements on Its .current vl.ews with respect to future .events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to .ri.sks, uncertaintie.s and assumptions, including, among .0th.er things: our recent emergence from bankruptcy, whic.h .c.o.uld adversely affect our busine.ss and relationships and subjects us to ri.s.ks and unc.e.rtainties.; competition from .0th.er .weight management .and health and wellness industry participants OJ the development .of more .effe.ctive .or more favorably perceived weight management methods; our failure to continue to retain and grow our subscriber base; our ability to be a leader in the rapidly evolving .and increasingly competitive .clinical weight management .and weight los.s market; our abllity to .c.ontinue to develop new, .innovative .s.ervi.c.e.s and products and .enhanc.e our existing .s.ervi.c.e.s and products or the failure of our .servic.e.s, products or brands to .c.ontinue to appeal to the market, .or .our ability to successfully expand into new .channe.ls .o.f di.stribution .or respond to .consumer trends .or sentiment; our ability to successfully Implement strategic Initiatives; the effectiveness and efficiency of our advertising and marketing programs, including .the strength of our .s.ocial media presence; the impact on our reputation of actions .take.n by our franchisees, license.es, suppliers, affiliated provider .entitie.s, PC.s’ healthcare professionals, and other partners; the recognition of asset impairment charges; .the lo.s.s of key personne~ strategic partners or .consultants or failure to effectively manage and motivate our workforce; our chief .executive officer transition, and .our ability to appoint a new chief executiv.e officer with th.e required le.vet .of experience and expertise .in a timely manne.r; our ability to successfully make ac.Quisitions or .enter into .c.ollaborati.ons or joint venture.s, including our ability to successfully integrate, operate or realize the anticipated benefits of such businesses; unce.rtainties related to a downturn in general .e.c.onomic conditions or consumer confidence, including as a .re.suit of the existing inflationary .envi.ronment, changes in tariffs .and escalating trade tensi.o.ns, rising i.nterest rates, th.e potential impact of political and social unrest and increased volatility in the credit and capital markets; the .seasonal .nature of our business.; our failure to maintain effective .Internal control over financial reporting; .the impact of events that impede accessing resources or discourage or impede people from gathering with others.; the early termination by us of leases.; the inability to renew .certain of our Uc.enses, or the inability to do so on terms .that are favorable to us; .the dependence of our payments system on third-party .s.e.rv.i.ce providers; .the impact of our exposure to variable rate ind.e.btednes.s.; the ability to generate .sufficient .cash to service .our .debt and satisfy .our .0th.er liquidity .re.Qui.rements; .unc.e.rtainti.e.s regarding th.e satisfactory operation .o.f .our technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compUance with evolving privacy laws and regulations; our ability to successfully integrate .and .use artificial JntelLigence in .o.ur busine.s.s; our abUity to enforce our .intellectual property rights both domestically and internationally, as well as the impact of our involvement in any .claims .re.late.d to .intellectual property rights; th.e impact .o.f existing and .future .laws .and regulations; risks .relate.d to our exposure to extensive and complex healthcare .laws and regulations; the outcomes of litigation or regulatory actions; risks and unc.e.rtalnti.e.s .associated with our lnternati.o.nal operations, including regulatory, .economic, politica~ socia~ lnteUe.ctual property, and foreign currency Ji.sks, which .risks may be exacerbated as a result of war .and terrorism; our ability to engage in share repurchases and pay .c.ash dividends in the foreseeable future; risks related to the acti.ons of activist .shareholders .and anti.-.take.ov:er provisions .in our articles of Incorporation and bylaws; risks related to the actions .of our shareholders and the .exclusive forum provisions in .our articles of incorporation; the possibility .that we .could fail to maintain the listing of our common stock on Nasdaq; an.d .other risks and uncertainties, including those included in this shareholder letter and those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission (the “SEC”) (which are avai.lable on the .S.EC’.s .ED.GAR database at www.sec.gov and via the Company’s .webs.ite at corporate.ww.com). You sho.uld .not put undu.e reliance .on any forward-looking statements. Yo.u .shou.ld .und.erstan.d that many important .factors, .Including .those discussed here.In, .c.ould cause the Company’s results to differ materially from th.ose expressed or suggested In any forward-looking statement. Except as required by law, the Company does not undertake any obUgation to update or revise these forward-looking statements to reflect new information or events .or .circumstanc.e.s .that occur after .the date of .this .shareholder letter .OJ to reflect th.e occurrence of unanticipated events .or .otherwis.e. Readers are advise.d to review the Company’s filings with th.e .SEC (which are available .on th.e S.EC’s ED.GAR database at www.sec.gov and via the Company’s website at corporate.ww.com). -I I 21

Reconciliation to GAAP Measures of Non-GAAP Financial Measures To supplement the Company’s .cons.olidated re.suits presented in ac.c.o.rdance .with accounting principles generally accepted Jn the .United .States (“GAAP”), the Company .has disclosed non-.GAAP .financial measures .of ope.rating .results that .exclude .or adjust .c.e.rtain .items. lll.e Company presents In this letter non-GAAP financial measures, Including earnings before Interest, taxes, depreciation and amortization expenses and .share.-based compensation expense (“EBITDA”J; and for .each period presented, .EBITDA adjusted, as applicable, for (a} good.will and .other ind.e.finite.-lived intangible asset impairments, (b) reorganization .items, net re.lated to the Company’s emergence from its Chapter .11 financial reorganization, (c) gain on extinguishment of debt, (d) transacti.on costs relate.d to strategic altemative.s and th.e Company’s Chapter 11 financial reorganization, (e) net restructuring cha!lles associated with the previously disclo.sed .2025, 2024, and .2023 restructuring plans, (t) severance and .re.lated fees for .certain former .exe.cutive .offi.c.ers, and (g) .other .items such as .the impact of foreign exchange gains and losses as indicated Jn the reconciliations below that management believas are not indicative of ongoing operations (“Adjusted EBJTDA”). The Company als.o presents gross profit, gross margin, marketing expenses, selUng, general and administrati.ve expenses, and product development expenses .o.n a non-.GAAP basis that adjusts .tor similar Items, as .further indicated in .the re.c.onclllatlons .lnclude.d .elsewhere In this .share.holder le.tter. In additi.on, .the Company presents .certain of its financial .re.suits on a constant currency basi.s in additi.on to .GAAP .re.suits .. Constant currency information compares .re.suits .between periods as .if exchange rates .had remained constant period-over-period. lll.e Company .calculates .c.o.nstant currency by calculating current-year .results using prior-year foreign currency exchange .rates. Management .beUeva.s .these non-.GAAP financial measures provide useful supplemental information for .its .and .investors’ .evaluati.on of .the Company’s busine.ss performance and are useful for period-over-period comparisons of the performance of the Company’s bus.ines.s. Whi.le management believes that these non-.GAAP .fi.nanc.ial measures are use.fut in evaluating the Company’s business, this .information .should be considered as supplemental In nature and Is .not meant to be considered In lso.latlon or as a substitute for the related financial information prepared in ac.c.ordance .with .GAAP. .In additi.on, the.se non-.GAAP financial measures may not be .the same as similarly titled measures reported by .other companies. See “Re.c.onciUation to .GAAP Measures of N.on-.GAAP Financial Measures.” in to this sharehold.er lette.r and reconci.liations, .if any, .included .e.ls.ewhere .in this shareholde.r letter for a reconci.liatio.n of th.e non-.GAAP financial measures to the most directly comparable GAAP me.asures. A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided .with.out unreasonable effort becaus.e of the .inherent difficulty of accurately forecasting the occurrence .and financial impact of the various adjusting items necessary for such .recon.ciLiation that .have not yet occurred, are .out .of the Company’s contro~ .or .cann.ot .be reasonably predicted. For th.e same .re.asons, the Company ls unable to assess the probable significance of .the unavailable .Information, .whlch .could have a material Impact on its future GAAP financial results. -I I 22

Operational Statistics {In Thousands, Except Percentages and Monthly Subscription Revenue Per Average Subscriber) Unaudited Successo r --C-om-bin-ed -- Three Months Ended Three Months End ed June 30, 2026 ~ ~ ~ (Constant Currency) (Constant Currency) 2,463 197 NIA NIA 3,299 135 (25.4%) 45.9% NIA NIA Incoming Subscribers’11 Incoming Behavioral Subscribers lncomin’ Clinical Subscribers lncomin Subscribers 2,659 I IA 3,434 22.6% NIA End of Period Subscribersl21 End of Period Behavioral Subscribers End of Period Clinical Subscribers 2,291 197 NIA NIA 3,040 127 (24.6%) 55.7% NIA NIA End of Period Subscribers 2,489 NIA 3,167 (21.4%) NIA Monthly Subscription Revenue Per Average Subscriberl’1 Monthly Beha..,oral Subscription Revenue Per Average Subscriber Monthly Clinical Subscription Revenue Per Average Subscriber 17.04 $ 67.55 $ 16.92 67.55 16.54 78.00 3.0% 2.3% (13.4%) (13.4%) Monthly Subscription Revenues Per Average Subscriber $ 20.90 $ 20.80 $ 18.97 10.2% 9.6% Nata: TotalS may not &WTI aua to rourdlrG- {1) The Jncomlng $Jlbaerllara’ ma1J’lc reJXll’.lfl WW~ In CoJ’npanv--w! .:,p&ralloNI 81:. _,_., pallod ~ 12) The “End Qf l’l:rbd Subac:rlbem” mctrlc 11:llOrla WW aibacrlbcn Jn ~ ~-aglven PCI!od end. J3l 1l19 “Monthly _Subacdptton Ravenua f’lll” Awnlg9 .Subacrller.” matrlc mpata .Iha manlhly reu 8ll80Clat8d .wlltl subacrJpllana fllr .Iha ComlNll1Y’B allllJlngs dlvldad by .the AwrBee &mcl1llar for 118 ~ MomlllY SUllacJlptlon R..nua .for Quanarty P8J10llll .ror each raspacttw ll.Uslnass 18 calculatad as SUbacrJpl!an Rava\u9 dlVilad by lll8 nwnllar ar monlhl In .ltla raspaet!Wl _quartarty par[od. The ~Alnlraga Silblcrlllar” .for _quartarty parlods .rar - r8ll)lllllllla bus!Nlas Is .Iha -,iaa al !ta ln00mlrG .Silblcrllfftand End al ParkX:t llUllllcrlbilrB for Iha raal)IIC1!ve .QU8J’ler!y period. Revenue - Constant Currency (In Thousands, Except Percentages); Unaudited Successor Three Months Ended June 30, 2026 Three Months Ended June JO, 2025 Van.ance GMP Constant Currency Combined(‘! 2026 vs 2025 Combined 2026 Constant Currency vs. 2025 Combined Total Revenue121 162,324 s 161.523 169,163 (1 4.2%) Behavioral Subscription Revenue<3l s 121.486 $ 120,689 $ 157,258 (22.7%) Clinical Subscription Revenue<> s 39,906 s 39,908 $ 30,593 30.4% Subscription Revenue<5l s 161,392 $ 160,597 $ 187,851 (14.1%) Other Revenue(e) s 932 s 926 s 1,312 (29.0%) Nole: Totals may not sum due to rounding. Nola: JlllaJS may not &WTI Jlll8 to lourdlrG- {1) :Theaa llfflllllnlll eanblna tha NWBIUIII at’.tha ~ and PJ’.8daeMloJ pll1,xla tor~ pwilHM ~ Iha~ and p-, have atllffamntaceowtllng baall ~-to .the app.llcatlan Ill .fmlh mrt RCIQQUJltlng. none Qf .the hah atwt accounllng mUuatrnentlllmJlact.llMlrute. lhen:foe, .the comblne.d - ang.unt11 praiented are oona1s1:mrt with a in> 1Drnw.PJ9Jllllllallcrl undar Arllclll .nor Regulation S-Xaslr ft:aah start accounting waa applied at.Iha 1>11g1nn1ng or .lhe llnltperlodl)nlllllJllad. l2l .”.RIMln.a” consists ar 1118 .BIIIIJBQalll ar ll.ubllcltpllon ~llllll 111\d Dlhllr ~ 1Jl ·-llUblicrllltktl - 00nslStS at’ .Iha 188& IIISIIClllrild wm, .subSCrlpllans frlr .lhs Ctlmpany& llahaVknl.Oll8rirGL 14l ¦aJnlcalSubecrlptlon ~ COl’lai.t. of Iha r.e. M80Cieled with aub8crll)llone for tha .0otnQanv’t Clinical~ J6l ‘Subacdptlon Rw.Bnuw’ Ill .tha IWn of Bahavlaral Subacdptlon Ravan.ua and CUnlcelSubecrlptlon Rw.Bnua. l8l .”Olhar.Rawnua” amsJs1B or IIMIRUII .Imm llcalllilnll, lranchl88.fllas with IIIBPllCt to aimmltmBnt pJanaWIII myaltlaa, p.ubllshlng and other ravanua. (14.6%) (23.3%) 30.4% (14.5%) (29.4%) -•• 23

Net (Loss) Income to Adjusted EBITDA (In Thousands, Except Percentages); Unaudited -I I ---------------------S-uc-ces-sor- -------------------- ---Pr-ede-ce-sso-r -- ___Q _2_2_0_26 _____Q _1_2_0_26 _____Q _4_2_0_25 _____Q _3_2_0_25 __ ~ ~ Netlncome (Loss) $ 14,074 $ (52 ,000) $ (5,833) $ (57 ,516) $ 1,254 $ 1,190,688 Net Income (Loss) Margm 8 7% (30 9%) (3 6%) (33 4%) 10 3% 672 7% Interest Taxes Depreciation and Amortization Expenses Share-based Compensation Expense 11 ,588 (11,155) 25,916 732 11 ,475 10,823 25,886 686 11 ,767 (1 8,856) 26,308 604 12,052 53,1 57 25,493 923 (523) 1,681 11 ,061 (20,906) 7,287 3,173 EBITOA $ 41 ,155 $ (3 ,130) $ 13,990 $ 33,186 $ 3,335 $ 1,191 ,303 EBITDA Margm 25 4% (1 9%) 8 6% 19 3% 27 4% 673 1% Reorganization Items, net < 1l (1,143,918) Gain on Extinguishment of Debt < 2l (4,612) Transaction Costs < 3l (514) 9,1 26 182 10,049 Restructuring Charges (4 ) (156) 468 4,584 122 (1,094) Severance and Related Fees < 5l 3,798 1,563 Other <6l (421 ) (737) (17) 342 932 4,478 AdJusted EBITOA $ 39,764 $ (1 ,836) $ 18,043 $ 42,776 $ 4,449 $ 60,818 AdJusted EBITDA Margm 24 5% (11%) 111% 24 9% 36 6% 34 4% Note: Totals may not sum due to rounding. (1) The net reorganization gain related to the Company’s emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject to compromise and the impacts of fresh start valuation adjustments. (2) Gain on extinguishment of debt consists of the Company’s voluntary prepayment in May 2026 of a portion of its New Term Loan Facility at 68.5% of par. (3) Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization. (4) Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. (5) Certain non-recurring expenses in connection with the separation from the Company of its former executive officers. (6) Primarily consists of the impact of foreign exchange gains and losses. 24

Gross Profit, Marketing Expenses, Selling, General & Administrative (SG&A}, Product Development Expenses Un Thousands, Except Percentages); Unaudited % of Revenue 70.3% 29.5% 4.0”/4 31.0% 73.2% 22.9% 5.6% 23.4% 73.7% 18.1% 8.0”/4 Adjustments Transaction Costs 111 (182) Depreciation and Amortization Expenses 5,331 (20,585) 33-0 (4) (1,347) 4,147 (54) Restructuring Charges t2J 156 (2,071) Share-based Compensation Expense (160) (109) (463) Severance and Related Feesm (3,798) Total Adjustments 5,332 $ (160) $ (109) $ (24,690) $ 330 $ (4) $ (1,529) $ 2,076 $ (54) $ % of Revenue 73.6% 29.4% 3.9% 15.8% 75.9% 22.9% 5.6% 10.9% 74.9% 18.1% 8.0”/4 Currency Adjustment (698) (41) (51 ) NIA NIA NIA NIA NIA NIA NIA % of Revenue 70.2% 29.6% 4 0% 31.1% NIA NIA NIA NIA NIA NIA NIA % of Revenue 73.5% 29.5% 3.9% 15.9% NIA NIA NIA NIA NIA NIA NIA Note: Totals may not sum due to rounding. (1) Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization. (2) Restructuring charges .cons.i.st of expenses .assoc.iated with the reducti.on .in head.count as a re.suit of .certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. (3) Certain non-recurring expenses In .connection with the separation from the Company of Its former executive officers. % of Revenue Adjustments: Transaction Costs <1J Depreciation and Amortization Expenses Restructuring Charges C2l Share-.-based Compensation Expense Severance and Related Fees 13) Total Adjustments 705% 5,180 (65) 5,115 55.2% 4.8% (141) (109) ( 141) $ ( 109) $ 28 6% (20,706) (533) (436) (1,563) (23,238) 70.1% 40.2% 5,350 1,618 6.968 5.4% (59) (59) 32.4% 514 (20,899) (2,966) (604) (23,955) $ 72. 1% 28.1% 5,135 23 5,158 24.2% (10,049) (3,086) (977) (3,171) (17,284) 14.4% NIA NIA NIA 4.4% (58) (58) $ -I I 34.9% (9,126) (20,301) (99) (29,525) AdJusted $ 123,787 $ 92,793 S 7,984 S 24,846 S 121 063 $ 65,474 $ 8,813 $ 28,733 S 129,269 $ 48,404 $ 7,492 $ 30,597 % of Revenue 73.6% 55.1% 4.7% 14.8% 74.4% 40.2% 5.4% 17.6% 75.1% 28.1% Note.: To.tats may not sum due to rounding. (1) Certain non-recurring transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization. (2) Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges .include the previously disclos.ed 2025 restructuring plan, .2024 restructuring plan, and 2023 restructuring plan . . (3) Ce.rtain non-recurring expenses in .conne.cti.on with the separation from the Company of its .former .executive officers. 4.4% 17.8% 25

.C.onaolldate.d .Balance .She.eta (In 1hllUaand8); .Unaulltad Successor June 30, Oecembe, 31, 2026 2025 ASSETS CURRENT ASSETS Cash and cash equivalents s 101,497 s 160,279 Restricted cash 5,796 6,298 Receivables (net of allowances: June 30, 2026 - S1 ,985 and December 31, 2025 - S1 ,651) 15,923 16,378 Prepaid income taxes 6,573 8,097 Prepaid marketing and advertising 3,079 9,275 Prepaid expenses and other current assets 14 017 13277 TOTAL CURRENT ASSETS 146,885 213,604 Property and equipment, net 6,886 6,115 Operating lease assets 2,148 2,933 Goodwill 199,910 200,135 Other intangible assets, net 453,289 490,664 Deferred income taxes 16,068 16,482 Other noncurrent assets 15256 14 625 TOTAL ASSETS s 840,442 s 946 756 LIABILITIES AND EQUITY CURRENT LIABILITIES Portion of operating lease liabilities due within one year s 991 s 1,260 Accounts payable 22,537 9,212 Salaries and wages payable 20,366 34,375 Accrued marketing and advertising 12,236 22,985 Accrued interest 867 1,084 Other accrued liabilities 21 ,527 23,049 Income taxes payable 2,333 6,006 Deferred revenue 25215 28565 TOTAL CURRENT LIABILITIES 106,074 126,536 Long.term debt, net 423,995 465,466 Long-term operating lease liabilities 1,325 1,893 Deferred income taxes 29,856 34,021 Other noncurrent liabilities 540 771 TOTAL LIABILITIES 561,792 628,687 EQUITY Successor common stock, SO par value; 1,000,000 shares authorized; 9.999 shares issued at June 30, 2026 and 9,992 shares issued at December 31, 2025 379,690 378,777 Accumulated deficit (100,021) (62,095) Accumulated other comprehensive (loss) income (1,019) 1 389 TOTAL EQUITY 276650 318,071 TOTAL LIABILITIES AND TOTAL EQUITY s 840 442 s 946 756 I i ..

Consolidated Statement of Operations (In Thouaandsf Except .Per .Share Amounts); Unaudited ---------S-uc-ces-sor- -------- ---P-re-dec-ess-or- -- Three Months Ended Period from June 25 2025 • Period from March 30, 2025 • ~ ~ ~ Subscription revenue, net <1> $ 161,392 $ 12,078 $ 175,773 Other revenue, net <2 > 932 89 1,224 Revenue, net 162,324 12,167 176,997 Cost of subscription revenue <3 > 48,015 3,258 46,439 Cost of other revenue 167 50 Cost of revenue 48,182 3,258 46,489 Gross profit 114,142 8,909 130,508 Marketing expenses 47,875 2,784 32,093 Product development expenses 6,441 686 14,160 Selling, general and administrative expenses 50,352 2,853 42,851 Operating Income 9,474 2,586 41 ,404 Reorganization items, net (1,143,918) Interest expense 11,588 923 11,061 Gain on extinguishment of debt (4,612) Other (income) expense, net (421) 932 4,478 Income before taxes 2,919 731 1,169,782 Benefit from income taxes (11,155) (523) (20,906) Net Income $ 14,074 $ 1,254 $ 1,190,688 Earnings per share Basic $ 1.41 $ 0.13 $ 14.81 Diluted $ 1.41 $ 0.13 $ 14.67 Weighted average common shares outstanding Basic 9,999 9,987 80,419 Diluted 10,001 9,987 81 ,165 Nata: 1btala ~ .not awn due .to 1DJ1ndlng. (1) “.SutllcJ’IIJ1IOn .rfMeftue, net” .conalata .or .the aggregate ar: 00 net .•sen1111o.r.a1 SUba.cllptlon Re:>.<enue.•, .tile fee.a .at80Cllted :wlll11.ubaalptlona .for the Compan(.s Bahavlo.ral .offarlngs; and (bl nat ~Unlcal Subacrlptlon Rnanua•, .the tau .IISIIOdatad .wttll aubacrlptlona .for Iha Campanys aJnlcal offllffnga. .(2) ~Othar IIMlnU8, nat” mnalata of J:aVBnua .f.mm llcanslng, .flBnchlaa .faaa .with mapact .to commitment plans and ~ltlaa, puhUahlng and o1har JIMll\ue. (3) ~Cast af subacrlptlan ftlVBnua• consists af .cost DI l8.11Bnua and apanrllng axpan•s far .Iha Company’s Beh8Yloral.and Cllnlcal aer.vlcaa. -I I

Consolidated Statements of Cash Flows Un Thousands); Unaudited Successor Predecessor ----------------------- ----------- SI x Months Ended Penod from June 25, 2025 June Penod from December 29, 2024 ~ _____~_ ._M_2_5 ___ ~ Operating activities: Net (loss) income $ (37,926) $ 1,254 $ 1,118,103 Adjustments to reconcile net (loss) income to cash (used for) provided by operating activities: Depreciation and amortization 51 ,802 1,681 14,201 Amortization of deferred financing costs and debt (premium) discount, net (51) 1,766 Impairment offranchise rights acquired 27,549 Impairment of intangible and long-lived assets 3 97 Share-based compensation expense 840 4,032 Deferred tax (benefit) provision (4,259) 26,232 Allowance for doubtfW accounts 27 {1,131) Foreign currency exchange rate (gain) loss (1,059) 933 6,717 Non-cash reorganization items, net (1,176,532) Early extinguishment of debt {4,612) Changes in cash due to: Receivables 227 466 4,280 Prepaid expenses 6,978 586 (31 ,281) Accounts payable 12,357 406 (8,237) Accrued liabilities (26,171) 6,178 15,084 Deferred revenue (3,178) 47 (2,914) Other long term assets and liabilities, net (599) 0 (2,234) Income taxes (3,654) (43) (30,155) Cash (used for) provided by operating activities {9,275) 11,508 (34,423) Investing activities: Capital expenditures (87) Capitalized software and website development expenditures (11,935) (188) (6,253) Other items, net (1) Cash used for investing activities (11,935) (188) (6,341) Financing activities: Borrowings on revolving credit facility 171,341 Financing costs (1,298) Payments on long-term debt (36,808) Taxes paid related to net share settlement of equity awards (145) Cash paid for acquisitions (16,000) Cash (used for) provided by financing activities (36,808) 153,898 Effect of exchange rate changes on cash and cash equivalents and restricted cash {1,266) 544 3,966 Net (decrease) increase in cash and cash equivalents and restricted cash (59,284) 11,864 117,100 Cash and cash equivalents and restricted cash, beginning of period 166,577 173,620 56,520 Cash and cash equivalents and restricted cash, end of period $ 107,293 $ 185,484 $ 173,620 - 28

Contact Information Investors Anna Kate Heller WetghtWatchers@icrinc.com Media Melissa Garbayo melissa.garbayo@ww.com ·••11• ••Luu11 a 29

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EX-99.1 430.6 KB
• EX-99.2 EX-99.2 75.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 12.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.2 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 13.7 KB